In order to discern trends in surgical procedures used to treat Meniere's disease in the United States during the 1990s, we mailed a questionnaire to 700 membe rs ofthe American Otological Society and the Ame rican Neurotology Society. These physicians were asked about the freq uency, results, and complications of surgical procedures for Meniere 's disease that they had performed between Jan. 1, 1990, and Dec. 31, 1999. Questionnaires were returned by 137 surgeons (19.6 %). Their responses indicated that the number of vestibular neurectomies, labyrinthectomies, and endolymphatic sac surgeries all decreased during 1999. Meanwhile, the use of officeadministered intratympanic gentamicin therapy increased rapidly throughout the entire 1O-year period, and by 1999 it had become the mostfrequently used invasive treatment f or Meniere's disease. Surgeons now seem to reserve inpatient procedures fo r cases where intratympanic gentamicin fa ils to control vertigo.
disease .' Because more than 10 years had passed since the completion of our previous survey, we thought it appropriate to conduct another to ascertain any new trends in surgeons' treatment preferences and outcomes in the surgical management of Meniere's disease. Specifically, we attempted to determin e the number of each type of procedure that had been performed, success rates, rates of hearing loss, complic ations, first-and second-line surgical treatment preferenc es, and respondents ' opinions regarding changing trends. In this article, we elaborate on these findings and others.
Methods and materials
We mailed questionnaires to virtually every member of the American Otological Society and the American Neurotology Society (n = 700) to ascertain trends in surgical procedures used to treat Meniere's disease in United State s citizen s between Jan. 1,1990, and Dec . 31, 1999 . Response data were entered into a Microsoft Excel 2000 spreadsheet and statistically analyzed with the assistance of a personal computer.
Results
Of the 700 questionnaires mailed, we received 137 responses (19.6%). Result s indicated that 79.6% ofrespondents were fellowship-trained, 81.0% had performed vestibular neurectomie s, 89.8% had performed labyrinthectomies, 85.4% had performed endolymphatic sac surgery, and 72.3% had used intratympanic gentamicin therapy (table). A clear trend emerged over the lO-year period in that there was an exponential increase in the use of intratympanic gentamicin therapy; the number of such procedures rose from fewer than 100 in 1990 to more than 900 SILVERSTEIN, LEWIS, JACKSON, ROSENBERG, THOMPSON , HOFFMANN Number of the 111 respond ents who performed vestibular neurectomi es who used .. . only the posterior fossa approach: 78 (70 .3%) only the middl e fossa approach : 9 (8.1 %) , both approaches: 24 (21 .6%) Numbe r of the 111 respond ents whose vertigo cure rates were between . . . 90 and 100% : 96 (86.5 %) 80 and 89 %: 13 (11.7 %) 70 and 79% : 1 (0.9%) <70%: 0 . no answer: 1 (0.9%) Number of the 111 respondents according to the percentage of their pati ents wh o experienced hearing loss (either a 1O-dB hearing loss or a 15 % decrease in speech discrimination score) following surg ery . . . oto 10% of pati ents: 76 (68.5%) 11 to 20 % of pat ients : 21 (18.9%) 21 to 30 % of patients : 10 (9.0%) 31 to 40% of pat ients: 1 (0.9%) >40% of patients: 2 (1.8%) no answ er: 1 (0.9%) 186 Number of 109 respondents who answered who felt that the number of neurectomies was . .. decreasing : 7 7 (70.6%) increasing: 4 (3.7%) remaining constant: 28 In addition, the following adverse events~3% inci dence) were reported at dosing of 20 mg/day in the controlled cli nical trials: Headache (13%), Flu Syndrome (9%), Dyspepsia (7%), Di zziness (6%), Pain (4%), S i nu~tis (4%), AbdominalPain (3%), Vomiti ng(3%), Pharyngitis(2%), Rash (2%), Infection (2%). The followingeventswere reportedin Sjogren's patients at incidences of 1% to 2%atdosing of20 mg/day: accidental injUry, allergic reaction, back pain, blurred vision, constipation, increased cough, edema, epistaxis, face edema, fever, flatulence, glossitis, lab test abnormalities, induding chemistry, hematology, and urinalysis, myalgia, palpllation, pruritis, somnolence, stomatitis, tachycardia , tinn itus,urinary inco ntinence,urinary tract infecti on,vaginitis. The following events were report ed rarely in treated Sjogren'spalients« I %)atrlosing of 10-30mg/day:causal relalionisunknown. Chest pain,cyst, death, m on i l i a~s , nec k pain, neck rigidity, phet osensitivity reacti on, angi napectoris, arrhythmia, ECG abnormality, hypotension, hypertension, intracranial hemorrhage, mi graine, myocardial infarction, anorexia, bili rubinemia, ch o l e l i t h i a~s , col itis, dry mouth, eructation, gastritis, gastroenteritis, gastroint esti nal disorder, gingi vitis , hepatitis, abnormal liver function tests, mel ena, nausea & vomiting, pancreatitis, parotid gland enlargement, salivary gl and enlargement, sputum increased, taste loss, tongue disorder, tooth disorder, hematur ia, lymphadenopathy, abnormal platelets, thrombocythemia, thrombocyt openi a, thromb osi s, abnormal W8C, peripheral edema, hypogl ycemia, arthralgia, arthritis, bone di sorder, spontaneous bone fracture, pathological fracture, myasthenia, tendon disorder, tenosyaovlns, aphasia, confusion,depression,abnormal dreams, emoti onal lability, hyperkinesia, hypesthesia, insomnia, leg cramps, nervousness, paresthesias, abnormal thinking, tremor, bronchitis, dyspnea, hiccup, laryngi smus, laryngitis, pneumonia,viralinfection,voicealteration,alopeci a,contact dermatitis,dryski n,eczema, erythemanodosum, exf oli ative dermatitis,herpessi mplex, ski n ulcer , vesi culobullous rash, cataract , conjunctivi tis,dryeyes, eardisorder, ear pai n, eye diSOfder, eye hemorrhage, glaucoma, lacrimat ion disorder, retinal disor der, taste perversion,abnonnal vi sion, breast pain, dysuria, masti tis, menorrhagia, metrorrhagia, ovarian disorder , pyuria, salpingiti s, ure thral pain, uri nary urgency , vaginalhemorrhage,vaginal moniliasis. The following adverse experiences have been reported rarely wi1h ocular pilocarpine: A-V block, agitation, cili ary congestion, confusion, delusion, depr ession, dermatitis, middle ear disturb ance, eyelid twitching, malignant glaucoma, iri s cysts, macul ar hole, shock, and vi sual hallucination.
MANAGEMENT OF OVERDOSE: Fa tal overdosage lvi th pilocarpinehas been report ed in the scientinc literature at doses presumed tobegreater than 100mgin2hospitalized patients. 100 mg of pil ocarpine is considered potentiall y fatal. Ov erdosageshould be treatedwithatropinetitration (0.5 mg to 1.0 mggiven subcutaneously or intravenously) and supportive measures to maintai n respiration and ci rculation. Epinephrine (0.3mgto 1.0 mg, subcut aneously or Intramuscul ariy) mayalso beofvaluein the presence of severe cardiovascular depressionorbronchoconstriction. It is notknown if pilocar pine is dial yzable.
OOSAGE AND ADMI NISTRATION:
Regardless of the indi cat ion, the starting dose in patients with moderate hepatic impairmentshoul d be 5 mg twice daily ,followedbyadj ustment basedontherapeuticresponse and tolerability. Patients with mild hepati c insufficiency do not requi re dosage reductions. The use of pilocarpine in patient s with severe hepat ic insufficiency is not recommended.If needed,refertotheHepatic Insufficiency subsection of the PRECAUTIONS sect ion of this label for definllionsofmild,moderate and severehepaticimpairment. Head& Neck Cancer Patients: The recommended initi al dose of SAlAGEN' Tablets is 1 tablet (5 mg) taken 3 times a day. Dosage should be adj usted accordingtotherapeutic response and tolerability. Theusual dosagerangeis3-6tablets or15-30 mgper day. (Not to exceed 2 tablets per dose.) Al though early improvement may be realized, at least 12 weeks of uninterrupted therapy with SAlAGEN' Tablets may be necessary to assess whether a benefici al response will be achieved. Thema jorityofpatientswere between40and 69 years(70%), 16% were 70 years and older and 14% were younger than 40 years of age. Of these pati ents, 161/629(B9/376receivingpilocarpine)were over theageof 65 years. The adverse events report ed by those over 65 years and those 65 yearsand younger were comparable except for notable trendsfor urinaryfrequency,diarrhea,and dizziness.The incidences of urinary frequencyand diarrhea in theel de~y were about double those in theno n -el de~y . The incidenceof dizzinesswasabout 3 timesashighinthe elderiy as in the no n -el de~y . These adverse experiences were not considered to be serious. In the 2 placebocontrolled studies, themost commonadverse events related to drug use were sweating, urinaryfrequency, chills, and vasodilatation (nushing). Drug Interactions: Pilocarpineshouldbeadministered lvith cautio n to patients taking bet a adrenergic antagonists becauseof thepossibilityof conductiondisturbances.Drugs wi1h parasympathomimetic effects administered concurrenUy with pilocarpine would be expected to resutt in additive pharmacologic effects. Pilocarpine might antagonize the anticholinergic effects of drugs used concomitantly. These effects should be considered when ant icholinergi c properties maybecontributing to the therapeutic effect of concomitant medication(e.g.,atropine, inhaled ipratropi um). While no formal drug interaction studies have been pertormeo,thefollowing concomilant drugs wer e used inat least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic aci d, artificial tears, calci um, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitami ns, naproxen, omeprazole,par acetamol,and prednisone.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Ufetimeoral car ci nogenicitystudies wereconducted in CD-1miceandSprague-Dawley rats.Pilocarpinedidnotinduce tumors in mice at any dosage studied (upto 30 mgikg/day, which yielded a systemic exposureapproximately50times larger than the maximum systemic exposure observed clini cally). In rats, a dosage of 18 mgikg/day, which yielded a systemic exposure approxi mately 100times larger than the maxi mum systemic exposure observed clinically, resultedinastatisti callysigni ficant increaseintheincidence of benignpheochromocytomas Inboth males and femal es, and a statisti cally si gnificant increase in the incidence of hepat ocellular adenomas in femalerats.Thetumorigenicity observedinratswasobservedonly at alargemul tipleof the maximumlabeled clinical dose, and may not berelevant to cli nical use. No evidence that pilocarpine has the pot ential to cause genetic t o~c i t y was obtained in a series of studies that incl uded: 1) bacterial assays (salmonella and £ coli) for reverse gene mutations; 2) an in vitro chromosome aberration assay In a Ch inese hamster ovary cell line;3)an in vivo chromosome aberration assay (micro nudeus test) in mice; and 4) a pri mary DNA damage assay (unscheduled DNA synthe~s) in rathepatocyteprimary cultures. Oral administrationof pilocarpinetomal eandfemaleratsat adosage of 18 mglkg/day, whichyieldedasystemic exposure appro~mateJy 100times larger thanthemaxmum systemic exposure observed clini cally, resulted in impaired reproducti ve function, including reduced ferti lity, decr eased sperm motility, and morphologic evidence of abnonnal sperm. ttisunclear wheth erthereducti oninfert ilitywasdue to effects on mal e animals, fema le animals, or both males and femal es. In dogs, exposure to pilocarpine at a dosage of 3 mgikg/day (a pp ro~m ate Jy 3 times the maximum recommendedhumandosa whencomparedonthebasi sof bodysurt acearea (mg/m')estimat es) for6 monthsresutted inevidenceof Impairedspermat ogenesi s.The dataobtai ned in these studies suggest that pilocarpine may impai r the fert ility of male and female humans. SALAGEN' Tabl et s sheuldbeadministered toindividual swho are attemptingto conceive achi ldonl yif thepotentialbenefitjustifiespotential impairmentof fertility.
Pregnancy:Teratogenic Effects Pregnancy CategoryC: Pilocarpinewasassociated with a reductionin the meanfetalbody weightandan increase In the incidenceof skeletal variat ionswhen given to pregnant rats at a dosage of 90 mgikg/day (appro~m a t e l y 26times the maximumrecommendeddosefor a50kghumanwhen compared on the basis of body surtace area (mg/ m') estimates). These effects may have been secondary to mat emal tO Xicity. In another stUdy, oral administration of pilocarpi netofemaleratsduringgestationand lactationata dosage of 36 mgikg/day (approXimately 10 times the m~mu m recommended dose for a 50 kg human when compared on the basis of body surtace area (mg/m') esti mates) resultedin an increased incidence of stillbirths; decreasedneonatalsurvival andreduced meanbody weight of pups were observed at dosages of 18 mgikg/day (apprOlomately 5 times themaxmum recommendeddose fO( a 50 kg human when compared on the basis of body surtace area (mg/m') estimates) and above. There areno adequate and well -controlled studiesin pregnant women. SAlAGEN' Tablet s should be usedduringpregnancyonl y ff thepotential benerri justifies thepotential risk tothefetus.
Nursing Mothers: tt is not knovm whether this drug is excreted in humanmilk.Becausemany drugsare excreted in human milk and because of the potential for serious Adverse Event adverse reacti onsinnursinginf ant sfromSALAGEN' Tablets a d e ci s i~n should be madewhether to discontinue nursing or to discontinue the drug, taking into account the importanceof thedrugtothe mother . But for patients who still maintain functional hearing, vestibular nerve section, endo lymphatic sac surgery, and intratympanic aminoglycoside therapy shou ld be cons idere d. In our 1992 survey, we found that the popularity of vestibular neurectomy had grown significantly during the preceding decade.' In fact , by the end of the study decade, it had become the most favored procedure, and surgeons were achieving excellent vertigo-control rates in patients with serviceable hearing. A decade later, a gradual decline in the number of neurectomies is evident, and surgeons have shifted their treatment strategies toward more conservative initial surgical approaches-that is, endo lymphatic sac surgery, whic h is associated with a low incidence of mor bidity, and intratympanic gentami-\ cin, whic h was new and not widely used in the United States at the time of our previous report. Today, vestibular neurectomy and labyrinthectomy appear to be reserved for patients who have not responded to the more conservative methods and for those without hearing.
Cer tainly, many limitations are inherent in the survey method of data collection in general and in our survey in particular. It is possible that some respondents did not review their resu lts in detai l before answering the questionnaire. Responses often appeared to reflect impressions rather than prec isely calculated figures. Moreover, data were not gathered by each respondent in a controlled or prospective fashion . Finally, approximately 80% ofthe members of the American Oto logical Society and the American Neurotology Society did not respo nd. We are unab le to draw any conclusions regarding the nationwide treatment of Meniere ' s disease, given such a large number
Discussion
For many years , the mainstay of therapy for symptoms of classic unilateral Meniere's disease included various medical regimens such as low-salt die ts, diuretics, carbonic anhydrase inhibitors, betahistine and other vasodilators, calcium channel blockers, and vitamin supp lements. Ver tigo-control rates of 87% and higher have been reported with these con servative measures. The management of patients who do not respond to such conservative therapy has been controversial. For patients who already have a significant hearing loss, labyrinthectomy is a viab le and straig htforward option.
in 1999 (figure 1). There was also an overall increase in the number of 1,000 -.--------------------, endolymphatic sac surgeries performed over the entire 1O-yearspan , althoug h a sharp decl ine was seen in the final year of the study. The number of labyrinthectomies remained fairly constant throu ghout the decade, and the number of vestib ular neurectomies slowly declined. By the end of the decade, intratympanic gentamicin therapy had rise n from the least-used modality to the most frequently used . More than half (53.8%) of the 106 respondents who answered this particularquestion said they were treating more Meniere's disease patie nts with intratympanic gentamicin be- Figure 1 . Numb er ofprocedures performed by respondents during each year ofthe 10-year cause it is minimally invasive and survey. Note the dram atic rise in the use of intratympanic gentamicin. can be performed in the office.
Vertigo-contro l ra tes varied amo ng the four treatments. Cure rates of 90 % or better were reported following 86.5% of the vestibular neurectomies, 90 .2% of the labyrinthectomies, 6.0% of the endolymphatic sac surgeries, and 29.3% of the intratympanic gentamicin procedures (figure 2).
While information regarding the incidence of complications associated with eac h procedure was solicited in the questionnaire, responses were sparse; this made it difficult to draw generalizations or conclusions. We did determine that endolymphatic sac surgery resulted in a lower incidence of postoperative hearing loss than did either vestibular neurectomy or intratympanic gen tamicin ( figure 3) .
As first -line surgical treatment, 48.9 % of the 137 respondents chose endolymphatic sac procedures, while 33.6% opted for intratympanic gentamicin. For secondline treatment, vesti bular neurectomy was preferred by 40.1 % of respondents, followed by labyrinthectomy at 17.5%. patients, and high incidence of complications, including hearing loss and facial weakness.
In 1972, Hitselberger and Pulec described the retrolabyrinthine approach for trigeminal nerve sections. I? Later, Silverstein and Norrell reintroduced vestibular neurectomy via the posterior fossa approach." Their method involved microsurgical techniques, theretrolabyrinthine approach, and mastoidectomy.P:" In the 1980s, this procedure and others that involved subsequent modifications of the posterior fossa approach became popular techniques for relieving vertigo while preserving hearing.
Intratympanic gentamicin. The popularity ofthe minimally invasive intratympanic aminoglycoside procedure increased dramatically during the 1990s. Developed in Europe by Beck and Schmidt'? and Odkvist." this treatment has become more common in North America largely as a result of the work of Nedzelski et al." According to our latest survey, the number of gentamicin procedures increased more than 13-fold during the 1990s, and it is now the most widely used treatment modality.
The fact that antibiotics cause ototoxicity became evident decades ago when streptomycin was first used for the treatment of tuberculosis." In 1948, Fowler published one of the earliest reports of the intentional application of streptomycin toxicity . 23 We must credit Schuknecht, however, with developing a method of delivering topical antibiotics to patients with unilateral Meniere's disease . In of unrepresented surgeons. Nevertheless, we believe that the responses we did receive provide a great deal of valid information about changing trends in surgical techniques and thought processes .
Endolymphatic sac surgery. Numerous reports on endolymphatic sac surgery have appeared in the literature, and several procedures have been proposed to control or eliminate the symptoms of Meniere 's disease. P These procedures include the use of the endolymphatic sac-mastoid shunt, the endolymphatic sac-subarachnoid shunt, and wide endolymphatic sac decompression. Endolymphatic sac-mastoid shunt surgery was first described by G. Portmann in 1927. 4 In a 1969 report of a large series of patients who had undergone this procedure, M. Portmann found that vertigo was alleviated in 93% of patients .' Since then, variations on G. Portmann's original procedure have been described by Morrison," Paparella and Goycoolea,? Goldenberg and Justus, 8 Gibson, 9 Huang and Lin,1O and Arenberg, II and their vertigo-control rates ranged from 74 to 90% .
Perhaps the most controversial study of endolymphatic sac surgery was published in 1989 by Bretlau et aI, who compared it with simple mastoidectomy.P One might think that their finding that good vertigo control was achieved in approximately 70% of patients in both groups would have quelled much ofthe enthusiasm that had been generated for endolymphatic sac surgery. But such was apparently not the case, as our survey found that use of this procedure increased throughout most of the 1990s. This finding suggests that our respondents harbored doubts about the findings of Bretlau et al. Because sac surgery poses a limited risk to cochlear function, many surgeons continue to use it as a mainstay of the surgical management of Meniere's disease symptoms in order to preserve hearing.
Vestibular neurectomy. Vestibular nerve section is the most successful method of curing vertigo while preserving hearing in patients with Meniere's disease." Early vestibular neurectomies via the suboccipital approach were performed in the 1920s and 1930s by Dandy!" and McKenzie. 15 However, the procedure then went virtually unused from 1945 until 1961, when House introduced the middle fossa approach. 16 In subsequent years, the use of the middle fossa approach was not uncommon, but it never achieved widespread popularity, largely because of its technical difficulty, limited applicability in older equipped with a 3.25-mm diameter flexible flange (Micromedics; Eagan, Minn.). The patient places a dilute concentration of gentamicin (10 mg/ml) into an eardropper and instills it three times per day. The MicroWick gives patients the convenience and flexibility to treat themselves at home, and it has the advantage of allowing for sustained low-dose infusion. The therapeutic endpoint is determined when the physician notes the appropriate balance between the amount of vestibular ablation (as measured by electronystagmography) and the progression of hearing loss.
In conclusion, our data provide evidence that surgeons are becoming increasingly comfortable with intratympanic gentamicin. Its ease of administration means that its popularity should continue to increase as both a first-and second-line treatment. 1957, he published his report on the use of a middle ear catheter to perfuse streptomycin into eight vertigo patients ." Vertigo control was achieved in all eight, but five of them experienced a complete unilateral hearing loss. Since the publication of these pioneering studies , many other authors have reported excellent vertigo-control rates with intratympanic streptomycin, albeit at the expense of substantial associated hearing loss. Although it is still unclear which drug has the best profile with regard to maximum vestibulotoxicity and minimum cochleotoxicity in patients with Meniere's disease, most clinicians use gentamicin.
Various protocols are used to deliver gentamicin to the inner ear, including direct transtympanic instillation, blind injection, round window membrane microcatheterization, and injection via the Silverstein MicroWick.25-28 The standard gentamicin solution is a 40-mg/ml concentration. To minimize patient discomfort, most practitioners buffer the solution with sodium bicarbonate to achieve a final gentamicin concentration of 26.7 mg/m!. To determine when to discontinue therapy, many physicians use symptom control as the endpoint. Others titrate the doses to maintain good hearing or to achieve a desired reduction in vestibular response as measured by electronystagmography. These methods have been met with varying degrees of success, but hearing loss is still a concern.
Some surgeons have contemplated the benefits oflowdose continuous-infusion therapy in an effort to maximize vestibular ablation while minimizing damage to the cochlear reserve. DeCicco et al reported excellent results with microdoses of dilute gentamicin (10 mg/ml) delivered though a microcatheter implanted in the round window niche." They reported no changes in hearing or reduction in vestibular response. Their findings suggest that gentamicin must relieve the vertigo of Meniere's disease by some mechanism other than the destruction of vestibular function. One possible explanation is that the gentamicin affects the dark cells of the vestibular labyrinth and the secretory cells in the stria vascularis, which reduces the secretion of endolymph, thereby reducing endolymphatic hydrops.
In 1998, Silverstein developed the MicioWick with these considerations in mind. 28 The cylindrical MicroWick is made of polyvinylacetate and measures 1 mm in diameter and 9 mm in length. It is placed through a silicone ventilation tube (inner ear diameter: 1.42 mm) that is 
